Listed

Celldex Therapeutics, Inc.

CLDXNasdaqCIK 744218HealthcareFiscal year ends Dec 31

Reports and events: 261 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Celldex Therapeutics, Inc., Reports and events
FiledFormWhat it isAccession number
2022-11-0916:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-22-007291
2022-08-0816:06 ET10-QQuarterly reportPeriod 2022-06-300001104659-22-087222
2022-08-0816:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-22-005457
2022-07-1816:01 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001104659-22-080483
2022-06-2316:03 ET8-K1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-22-073889
2022-06-1616:06 ET8-K5.07 Shareholder vote results0001104659-22-071880
2022-05-0516:06 ET10-QQuarterly reportPeriod 2022-03-310001104659-22-056442
2022-05-0516:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-22-003323
2022-04-2607:01 ETDEF 14AProxy statementPeriod 2022-06-160001104659-22-049942
2022-02-2816:06 ET10-KAnnual reportPeriod 2021-12-310001104659-22-028070
2022-02-2816:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-22-001448
2022-01-2816:01 ET8-K5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001104659-22-008977
2021-11-0916:05 ET10-QQuarterly reportPeriod 2021-09-300001104659-21-136268
2021-11-0916:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-21-007741
2021-08-0516:07 ET10-QQuarterly reportPeriod 2021-06-300001104659-21-100745
2021-08-0516:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-21-005572
2021-07-1416:05 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-21-092099
2021-07-1216:01 ET8-K8.01 Other events0001104659-21-091151
2021-07-0116:02 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001104659-21-088220
2021-06-1716:02 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-21-082585
2021-05-0616:06 ET10-QQuarterly reportPeriod 2021-03-310001104659-21-062387
2021-05-0616:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-21-003256
2021-04-2716:06 ETDEF 14AProxy statementPeriod 2021-06-170001104659-21-055589
2021-03-2916:06 ET10-KAnnual reportPeriod 2020-12-310001104659-21-043161
2021-03-2916:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-21-002135
2021-01-0408:07 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-21-000104
2020-11-0616:21 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-20-122521
2020-11-0516:06 ET10-QQuarterly reportPeriod 2020-09-300001104659-20-121786
2020-11-0516:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-20-007664
2020-08-1816:01 ET8-K8.01 Other events0001104659-20-096505
2020-08-0616:21 ET10-QQuarterly reportPeriod 2020-06-300001104659-20-091459
2020-08-0616:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-20-005651
2020-06-1816:06 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-20-074646
2020-06-1717:38 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-20-073843
2020-06-1516:10 ET8-K8.01 Other events0001104659-20-073386
2020-06-1216:29 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-20-072934
2020-05-0616:16 ET10-QQuarterly reportPeriod 2020-03-310001104659-20-057436
2020-05-0616:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-20-003372
2020-04-2816:09 ETDEF 14AProxy statementPeriod 2020-06-180001047469-20-002644
2020-03-2616:09 ET10-KAnnual reportPeriod 2019-12-310001047469-20-001809
2020-03-2616:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-20-002037
2019-11-1209:01 ET10-QQuarterly reportPeriod 2019-09-300001104659-19-062181
2019-11-1208:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-19-007429
2019-08-0716:06 ET10-QQuarterly reportPeriod 2019-06-300001104659-19-044531
2019-08-0716:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-19-005251
2019-06-2416:01 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-19-037195
2019-06-2016:01 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-19-036671
2019-05-0716:31 ET10-QQuarterly reportPeriod 2019-03-310001104659-19-027513
2019-05-0716:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-19-003062
2019-04-2609:02 ETDEF 14AProxy statementPeriod 2019-06-190001047469-19-002607

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.